Research team finds that protein motions regulate virus infectivity.Nearly 37 million people worldwide are living with HIV.
Source: HIV/AIDS news from Medical News Today
Month: November 2015
Population Council's MZC outperforms TFV 1 percent gel in microbicide candidate preclinical study
MZC microbicide gel demonstrates strong efficacy against HIV and HSV-2 in preclinical study.
Source: HIV/AIDS news from Medical News Today
New CDC estimates underscore the need to increase awareness of a daily pill that can prevent HIV infection
A new Vital Signs report estimates that 25 percent of sexually active gay and bisexual adult men, nearly 20 percent of adults who inject drugs, and less than 1 percent of heterosexually active…
Source: HIV/AIDS news from Medical News Today
'We have what it takes to break AIDS epidemic,' says UN report
A UN report celebrates and gives examples of the progress in tackling HIV/AIDS but also shows how far many countries are from the goal of ensuring everyone with HIV gets treatment.
Source: HIV/AIDS news from Medical News Today
In era of HIV treatment in South Africa, men see lower increases in life expectancy than women
Improvements in availability of antiretroviral therapy (ART) for HIV in South Africa over the past decade coincide with an increased gap in female versus male life expectancy, according to a study…
Source: HIV/AIDS news from Medical News Today
Modeling the global HIV treatment funding gap for 2020 targets
With currently projected funding, countries around the world are unlikely to achieve the Joint United Nations Programme on HIV/AIDS 90-90-90 treatment target (which includes 90% of people diagnosed…
Source: HIV/AIDS news from Medical News Today
Use of antivirals in retrovirus-infected cats
A number of antiviral drugs are licensed and widely used for the treatment of specific viral infections in humans.
Source: HIV/AIDS news from Medical News Today
HIV: European Commission grants marketing authorisation for Gilead's single tablet regimen Genvoya
Gilead Sciences, Ltd. have announced that the European Commission has granted marketing authorisation for the once-daily single tablet regimen Genvoya® (150 mg elvitegravir, 150 mg cobicistat…
Source: HIV/AIDS news from Medical News Today